https://doi.org/10.55788/0987f4cb
An observational study showed that frailty and severe comorbidity were strong predictors of death without appropriate therapy in patients with implantable cardioverter defibrillators (ICDs), suggesting that certain patients may not benefit from ICD therapy.
“Although ICDs decrease mortality by reducing the risk for sudden cardiac death, most patients with these devices do not receive life-prolonging therapy,” explained Dr David Wilson (Worcestershire Royal Hospital, UK). “Older patients and patients with numerous comorbidities may have an increased risk of non-arrhythmic death and the benefits of ICDs may therefore be reduced in these patients.”
The current prospective, multicentre, observational COMFORT-Q study included 662 patients with ICDs to investigate which are the most important contributors to ‘death with no appropriate therapy,’ which was the main outcome of the study. The research team asked the participants to complete several health questionnaires including the Fried frailty score, the 12-Item Short-Form Health Survey (SF-12), the EQ-5D-5L, and the Charlson comorbidity index. The mean age of the study population was 65.6 years, 23% were women, 12% of the participants were considered frail, and 11% of the participants had a severe Charlson comorbidity index.
After a follow-up of 2.5 years, 63 participants had died of whom 54 had died without receiving appropriate ICD therapy. Frailty was the strongest independent predictor for death without appropriate therapy (OR 3.41; P<0.001). Severe comorbidity (OR 2.72; P<0.001) and estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (OR 2.16; P<0.001) were other significant predictors for this event to occur. Age >70 years and an EQ-5D-5L score <0.6 were not significantly associated with ‘death without appropriate therapy’.
-
- Wilson D, et al. Co-morbidities, frailty, functional status in ICD recipients: The COMFFORT-Q study. Devices – Round 2 – Others, EHRA 2023, 16–18 April, Barcelona, Spain.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Statins display benefits for AF patients in a large population-based study Next Article
Does adaptive pacing work in patients with HF, LBBB, and intact AV conduction? »
Table of Contents: EHRA 2023
Featured articles
CEASE-AF meets primary endpoint in persistent AF
ANTWERP score selects HF patients for AF ablation
Ablation for Atrial Fibrillation
Surgery saves lives in patients with oesophageal fistula
MANIFEST-PF: Good results for the pentaspline PFA catheter
POWER FAST III: High-power, short-duration radiofrequency ablation for AF
High-power, short-duration ablation linked to a higher stroke risk
Early or delayed ablation for AF?
CEASE-AF meets primary endpoint in persistent AF
Promising results for Marshall Plan ablation strategy
Updates on Devices
Can ICD-EG-derived information improve ventricular tachycardia ablation outcomes?
Prolonged ECG monitoring detects relevant arrhythmias in HCM
Does adaptive pacing work in patients with HF, LBBB, and intact AV conduction?
Can we identify patients who may not benefit from ICD therapy?
Miscellaneous
Statins display benefits for AF patients in a large population-based study
ANTWERP score selects HF patients for AF ablation
Epicardial ablation successful in Brugada syndrome
Highly increased risk of arrhythmias after mechanical ventilation for COVID-19
Related Articles
First evidence of brainstem involvement in COVID-19
COVID-19 far more deadly than seasonal flu, large study confirms
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy